Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905147 | 0.94 | KDM4E (0.36) | KDM4EHTTSMN1; SMN2ALOX15 | |
| SCHEMBL4905518 | 0.83 | KDM4E (0.35) | KDM4EHTTSMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL4884582 | 0.77 | TSHR (0.36) | HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4886717 | 0.75 | LMNA (0.35) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4887120 | 0.71 | KCNH2 (0.35) | HTTSMN1; SMN2 | |
| SCHEMBL4905138 | 0.70 | TSHR (0.39) | KDM4EALOX15ALDH1A1 | |
| SCHEMBL4882617 | 0.70 | KCNH2 (0.34) | — | |
| SCHEMBL4879837 | 0.69 | KCNH2 (0.37) | HTTSMN1; SMN2 | |
| SCHEMBL4875978 | 0.69 | KCNH2 (0.33) | KDM4EHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14108423 | 0.68 | KCNH2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | POLRMT, POLR1G, POLR2A | KDM4E 792/4885HTT 2601/4885SMN1; SMN2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.